Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous...

Descripción completa

Detalles Bibliográficos
Autores principales: Leeneman, Brenda, Uyl-de Groot, Carin A., Aarts, Maureen J. B., van Akkooi, Alexander C. J., van den Berkmortel, Franchette W. P. J., van den Eertwegh, Alfons J. M., de Groot, Jan Willem B., Herbschleb, Karin H., van der Hoeven, Jacobus J. M., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Haanen, John B. A. G., Franken, Margreet G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225943/
https://www.ncbi.nlm.nih.gov/pubmed/32325748
http://dx.doi.org/10.3390/cancers12041003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225943/
https://www.ncbi.nlm.nih.gov/pubmed/32325748
http://dx.doi.org/10.3390/cancers12041003

Ejemplares similares